Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NCD Partnership

- PMLiVE

Lilly buoyant as lung cancer hope clears pivotal study

Necitumumab on course for regulatory submission in 2014

- PMLiVE

Boehringer eyes obesity market

Aims to widen metabolism portfolio beyond diabetes

- PMLiVE

Novo says three year wait for Tresiba safety data

Trial will start this year comparing insulin’s cardiovascular safety to that of Lantus

- PMLiVE

GSK’s diabetes hope albiglutide delayed in US

FDA extends deadline to April 2014

- PMLiVE

Lilly to support training of scientists from ethnic minorities

Pharma company will work with Roswell Park Cancer Institute

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

- PMLiVE

EMA: no new safety concerns with GLP-1 diabetes drugs

CHMP takes issue with study that linked the treatments to serious side effects

Sanofi Israel crowdsources new diabetes app

Collaborates with online patient network Camoni

- PMLiVE

Making mobile health technology work

Augmenting organic life with artificial technology is gaining ground in healthcare

Boehringer trials digital diabetes programme

Will study effect of self-management technology on clinical care

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links